T he prion diseases are transmissible, fatal, neurodegenerative disorders that may be inherited or acquired or that may occur spontaneously as sporadic Creutzfeldt-Jakob dis ease. 1 The transmissible agent, or prion, is thought to comprise misfolded and aggregated forms of the normal cellsurface prion protein. Prion prop agation is thought to occur by means of seeded protein polymerization, a process involving the binding and templated misfolding of normal cel lular prion protein. Similar processes are increas ingly recognized as relevant to other, more com mon neurodegenerative diseases. In prion and other neurodegenerative disorders, the aggregates of misfolded protein in the central nervous sys tem are highly heterogeneous, occurring as amy loid plaques, more diffuse deposits, and soluble species. The inherited prion diseases are auto somal dominant disorders caused by mutations in the gene encoding prion protein (PRNP). 2 These disorders have been classified into three over lapping neurologic syndromes: the GerstmannSträussler-Scheinker (GSS) syndrome, fatal fa milial insomnia, and familial Creutzfeldt-Jakob disease. 1 In contrast to the proteins forming abnormal deposits in other neurodegenerative diseases, prion protein is tethered to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. The development of transgenic mice that express prion protein lacking the GPIanchor addition site (known as "anchorless" prion protein) has been of considerable interest, since these mice may propagate infectious prions and abnormal prion protein deposits around blood vessels in the brain and peripheral tissues, but they show highly delayed and variable clinical signs of prion disease. 3, 4 In humans, a premature stopcodon mutation also results in abnormal prion protein without a GPI anchor, but clinical reports are very limited. The PRNP Y145X mutation has been described in a single patient with an Alzheimer type dementia and prion protein amyloid deposi tion in the cerebral vessels, 5 the Q160X mutation has been described in a small family with demen tia, 6 and two Cterminal truncation mutations have been associated with the GSS syndrome in case reports. 7 Here we describe the clinical, pathological, and molecular characteristics of a large kindred with a consistent and novel prion disease phenotype that is associated with chronic diarrhea and hereditary sensory and autonomic neuropathy caused by a novel PRNP mutation.
Me thods

Patients
The proband (Patient IV1) donated his brain to the Queen Square Brain Bank for Neurological Disorders, London, for research into the cause of his family's neuropathy. Analysis of human tissue samples and transmission studies in mice with the use of human brain tissue were performed with consent from relatives and approval from the local research ethics committee. Patients IV1, IV4, IV6, V2, and V7 provided written informed consent.
Immunohistochemical Analysis
After fixation of the tissue, we processed the tis sue blocks into paraffin wax with the use of stan dard protocols and pretreatment with formic acid. Tissue sections with a thickness of 7 μm were stained by means of routine methods, in cluding hematoxylin and eosin, Luxol fast blue, periodic acid-Schiff, Congo red, and thioflavin S. Immunohistochemical analysis was performed on the basis of a standard avidin-biotin protocol with the use of antibodies against prion protein (KG9, 3F4, ICSM 35, and Pri917 8 ), amyloid P com ponent, glial fibrillary acidic protein, tau (AT8), tau3R, tau4R, amyloidβ, neurofilament cock tail, TDP43, CD68, CR3/43, and αsynuclein. (For the results of transmission electron microscopy and other details, see the Methods section in the Supplementary Appendix, available with the full text of this article at NEJM.org.)
molecular Genetic and protein studies
We sequenced the entire open reading frame of PRNP from genomic DNA using standard tech niques. Aliquots of brain homogenate were ana lyzed with or without proteinase K digestion and with or without phosphotungstic acid precipita tion by means of sodium dodecyl sulfate-poly acrylamide gel electrophoresis (SDSPAGE) and immunoblotting (see the Methods section in the Supplementary Appendix).
Murine Models
Transgenic mice homozygous for a human pri on protein 129V transgene array and murine prion protein-null alleles (Prnp 0/0 ), designated 
R esult s
Clinical Syndrome
The clinical syndrome was similar in all the pa tients and was transmitted as a dominant trait (Fig. 1) . All the patients for whom clinical details were available presented with chronic diarrhea, with onset when they were in their 30s, followed by symptoms and signs of a mixed, predominant ly sensory and autonomic neuropathy (Table S1 in the Supplementary Appendix). Watery diarrhea was reported to occur several times daily and nocturnally and was associated with bloating and fluctuating weight, leading to diagnoses of the irritable bowel syndrome and Crohn's disease. Urinary retention caused by denervation of the bladder, which necessitated intermittent self catheterization, and impotence were early symp toms in two patients. Another early symptomatic feature was postural hypotension, which respond ed to therapy with mineralocorticoids and non pharmacologic supportive measures. In patients with moderately advanced disease, weight loss, vomiting, and diarrhea were severe, warranting the use of parenteral feeding in two patients. This treatment stabilized weight and helped relieve nausea and reduce diarrhea, benefits that per sisted when normal oral nutrition was reintro duced several months later. The onset of cogni tive problems and seizures occurred when the patients were in their 40s or 50s. The average age at the time of death was 57 years (range, 40 to 70).
Electrophysiological studies on 11 occasions in five patients consistently showed a progressive, lengthdependent, predominantly sensory, axonal polyneuropathy (Table S2 in the Supplementary Appendix). Thermal thresholds were markedly abnormal in the feet but not in the hands. Motor involvement was less severe, with evidence of de nervation, especially in distal leg muscles, at ad vanced stages. The clinical and electrophysiolog ical studies prompted the diagnosis of hereditary sensory and autonomic neuropathy, and the find ings are reminiscent of familial amyloid poly neuropathy.
Formal neuropsychological studies were per formed on eight occasions in three patients. The most prominent finding was impairment of memory and executive function when the pa The family pedigree shows that the disease follows a dominant transmission pattern. The solid symbols (squares for males and circles for females) indicate family members who were either affected or presumed to be affected; the proband is indicated with an arrow. The number below symbols with a slash is the age at death. Affected family members in generations II and III were not assessed in this study and were presumed to have been affected on the basis of the medical history provided by relatives and information obtained from medical records or death certificates. tients were in their 50s. Two of the markedly affected patients (Patients IV4 and IV6) showed phonologic language impairment. Magnetic reso nance imaging (MRI) of the brain showed gen eralized volume loss in the supratentorial com partment in one patient with advanced disease but was normal in the other patients. Exami nation of the cerebrospinal fluid showed an eleva tion of total tau (>1200 pg per milliliter; nor mal range, 0 to 320) and S100b protein (2.17 ng per milli liter; normal value, <0.61), and elevated amounts of 1433 protein in one patient. Cardiac assessments were carried out because cardiomyopathy occurs in transgenic mice ex pressing anchorless prion protein. 9 However, there were no indications of cardiac involvement in the patients' medical history or on examina tion; electrocardiography in six patients and echocardiography in three patients showed no abnormalities.
Molecular Genetics
Sequencing of PRNP in DNA samples obtained from patients who provided consent showed a nov el PRNP Y163X mutation. This mutation was found in association with valine at polymorphic prion protein residue 129 (c.489C→G, p.Y163X) (Fig. 2) . The polymorphism at codon 129 of PRNP is com mon in the healthy population and is known to be a strong susceptibility factor for prion dis ease, as well as a diseasemodifying factor. Three other patients with evidence of the clinical syndrome (Patients II2, III1, and III5) were deemed to be obligate carriers. No mutations were found in 18 unrelated patients in whom heredi tary sensory and autonomic neuropathy had been diagnosed at the National Hospital for Neurol ogy and Neurosurgery, which suggests that prion disease is not a common cause of this clinical syndrome. We have not seen this mutation in evaluations of more than 4000 patients and con trols. 10
Brain and Peripheral-Organ Disease
We hypothesized that this unusual clinical syn drome might be associated with an atypical path ological appearance and distribution of abnor mal prion protein. We therefore investigated the tissues obtained both on autopsy (in Patients IV1, IV4, and IV6) and on biopsy (in Patients V2 showed ex tensive focal accumulation of prion protein in the muscularis mucosae as plaques and more diffuse deposits in the lamina propria and submucosa (Fig. 3D) ; similar findings were present in several biopsy samples obtained from Patient V2. Histo pathological analysis of multiple internal organs obtained on autopsy from Patients IV4 and IV6 showed consistent, widespread, and extensive deposition of prion protein amyloid (Table S3 in the Supplementary Appendix).
In brief, granular staining was seen around ganglion cells in the dorsalroot ganglia and around nerve fibers in multiple peripheral nerves. Prion protein immunoreactivity was also con spicuous between axons of cranialnerve roots and those of dorsal and ventral roots in the spinal cord (Fig. 3C) . The peripheral lymphore ticular system was involved but showed a pattern of disease distinct from that seen in patients with variant Creutzfeldt-Jakob disease, with abnormal prion protein staining of lymphoid capsules and stroma. In the cardiovascular system, extensive deposition was seen around cardiac myocytes and in the walls of arteries and veins. The depo sition of prion protein was also seen in the portal tract of the liver, around kidney tubules, and in lung alveoli. Although abnormal prion protein has been detected in peripheral tissues of some patients with sporadic Creutzfeldt-Jakob disease with the use of highsensitivity Western blot techniques, abnormal prion protein has not been identified on immunohistochemical analy sis in such patients. [11] [12] [13] Histologic examination of neocortical regions of brain samples obtained from Patient IV1 showed mild spongiosis that was restricted main ly to cortical layers 1 and 2; findings in Patients IV4 and IV6 were similar. Vacuolation of deeper cortical laminae, which has been associated with some forms of sporadic prion disease, was not a prominent feature. We observed widespread pri on protein plaques and a substantial amount of taurelated disease in the form of neurofibrillary tangles and neuropil threads (Fig. 4 , and Table S4 in the Supplementary Appendix) -findings that are also seen in some forms of the GSS syn drome. Microglia also showed immunoreactivity for prion protein (Fig. 4C ) whereas neurons and astrocytes were unstained. Focal prion protein immunoreactivity in the walls of capillaries, of ten extending into surrounding neuropil, was most prominent in subcortical regions. The presence of protein deposits with amyloid con formation was confirmed with the use of the periodic acid-Schiff technique (Fig. 4A, inset) , which showed immunoreactivity for serum am yloid P component (Fig. 4D) . Ultrastructural examination of neocortex confirmed the pres ence of amyloid with the detection of small unicentric plaques composed of fibrils radiating at the periphery (Fig. 4L) . To determine whether nonmutant prion protein was recruited into de posits, immunohistochemical staining with the use of an antibody against the Cterminal of prion protein (Pri917, epitope 216-221) was per formed. 8 This showed a pattern of staining that was similar to that seen with the three other prion protein antibodies used in the study (Fig.  4K ), although molecular and transmission studies did not suggest that nonmutant prion protein is a participant in the disease process.
Immunoblotting
Abnormal prion protein in prion disease may be studied by means of Western blot analysis after partial digestion of the protein with proteases, revealing a diversity of fragment sizes and glyco sylation patterns that may correlate with clinical features. 14 We performed these molecular stud ies to compare abnormal prion protein in this condition with abnormal prion protein seen in other prion diseases. We analyzed 10% brain homogenate (weight per volume) prepared from frontalcortex samples obtained from Patients IV1 and IV6 before or after digestion with proteinase K. 15 After diges tion, Y163X brain homogenate showed a ladder of proteaseresistant fragments reactive to antiprion protein monoclonal antibody 3F4, with ap parent molecular masses ranging from approxi mately 10 kDa to more than 100 kDa ( Fig. 5A and 5B). 15 This pattern of diseaserelated prion protein fragments is highly unusual and con trasts markedly with the much more discrete patterns of truncated proteinase K-resistant prion protein fragments that are seen in other prion diseases. [16] [17] [18] [19] [20] Prion protein amino acids 23 to 162 have a molecular mass of approximately 14.6 kDa and lack the sites for known posttransla tional modification of prion protein by either Nglycosylation or the addition of a GPI anchor. The presence of proteinase K-resistant species of prion protein with apparent molecular masses much greater than expected for fulllength, digly cosylated, nonmutant prion protein suggests that prion protein encoded by PRNP Y163X may be forming stable sodium dodecyl sulfate-resistant oligomers. 5
Absence of Transmission to Mice
We performed studies using patients' brain tis sue to determine whether prion infection could be transmitted to mice. None of the 24 mice from three lines showed any clinical signs of prion disease up to 600 days after inoculation, when the experiment was terminated. We also analyzed brain samples for subclinical infection but observed no proteinase K-resistant prion pro tein on Western blot analysis or abnormal depo sition of prion protein on immunohistochemical analysis.
Discussion
We describe a novel clinical and pathological phenotype associated with a Y163X mutation in PRNP, a disorder that is of particular interest for several reasons. The phenotype is distinct from other prion diseases in that it is associated with a nonneurologic presentation, the widespread deposition of prion protein amyloid in systemic organs, and slow disease progression. These find ings highlight the possibility that there are pe ripheral abnormalities in other brain diseases associated with protein misfolding. Since the predominant symptoms are peripheral, patients often are referred initially to a gastroenterologist and undergo gastrointestinal endoscopy and bi opsy, before a neurologic opinion is sought; thus, the condition is a challenging one to diag nose. The unusually long and distinct clinical syndrome raises interesting mechanistic issues with respect to the role of the GPI anchor in prion High-sensitivity immunoblot analyses of prion protein were performed in frontal cortex obtained from Patients IV-1 and IV-6, both of whom had the PRNP Y163X mutation, to characterize protease-resistant prion protein as compared with known variation in prion disease. Panels A and B show 10 mm 3 of 10% frontal cortex homogenates (weight to volume) prepared from normal human brain, sporadic Creutzfeldt-Jakob disease brain (sCJD) (PRNP codon 129MM with type 2 abnormal prion protein; London classification 16 ), and brain tissue from Patient IV-1 (Panel A) and Patient IV-6 (Panel B), analyzed before (−) or after (+) digestion with proteinase K (PK) with the use of anti-prion protein monoclonal antibody 3F4. In the sCJD sample, three PK-resistant immunoreactive bands are seen, representing the dif ferent glycosylation states of prion protein with an N-terminal truncation. Because the smallest fragment of prion protein that was detected in PK-digested brain homogenate obtained from Patients IV-1 and IV-6 has an apparent molecular mass of approximately 10 kDa, it would appear that prion protein 23-162 is truncated by the protease. To investigate this further, phosphotungstic acid was used to precipitate disease-related prion protein from detergent-solubilized brain homogenate. 15 The pattern of PK-resistant fragments was then reanalyzed with the use of different anti-prion protein monoclonal antibodies. Panel C shows PK-digested phosphotungstic acid pellets derived from 33 mm 3 of 10% frontal cortex homogenate from Patient IV-1 with the use of anti-prion protein monoclonal antibodies ICSM 35, ICSM 18, and 3F4 or secondary antibody alone (2°Ab). PK-digested precipitant from the sample obtained from Patient IV-1 showed a pattern of PK-resistant fragments of prion protein equivalent to that seen after direct PK digestion of brain homogenate, except that the smallest species of prion protein (with an apparent molecular mass of approximately 10 kDa) was absent, in contrast to what is seen in Panels A and B. These findings suggest that the abnormal prion protein conformer that generates the 10-kDa fragment either is soluble in detergent and thus is not recovered by precipitation or becomes sensitive to proteolysis in the presence of detergent. All the remaining PK-resistant species of prion protein showed similar immunoreactivity and were reactive with anti-prion protein mono clonal antibodies ICSM 35 (epitope 93-105 of human prion protein) and 3F4 (epitope 104-113 of human prion protein) and nonreactive with anti-prion protein monoclonal antibody ICSM 18 (epitope 142-153 of human prion protein) or secondary antibody alone. The lack of reactivity of all prion protein species with ICSM 18 indicates that oligomers are composed of fragments of prion protein that are truncated at the C-terminal by PK. It also indicates that these data exclude the involvement of C-terminal protease-resistant conformers of nonmutant prion protein that characterize sporadic and acquired CJD and certain forms of inherited prion diseases. pathobiology and the toxicity of prion protein amyloid. Prion strains, which are associated with dis tinct types of misfolded prion protein, are known to be critically important determinants of toxic ity and pathological targeting. 21 The truncation mutation may result in misfolded prion protein with radically different strain properties. The relative contributions to observed strain proper ties of nonmutant prion protein, the lack of a GPI anchor, a truncation of the protein, and the association between the Y163X mutation and the presence of valine at polymorphic residue 129 are unclear. These issues might be further addressed by the generation of transgenic mice that express human prion protein with the Y163X mutation.
Two transgenic mouse models have been re ported that have homozygous expression of full length prion protein lacking the GPI anchor ("anchorless prion protein"). In both models, there are vascular and perivascular deposits of prion protein that are similar in appearance to those in the brains of humans who have inherited prion diseases with PRNP stopcodon muta tions. 3, 4 This finding suggests that the cerebro vascular phenotype associated with the deposi tion of prion protein may relate to the loss of the GPI anchor alone, rather than Cterminal trun cation of prion protein. One model in trans genic mice showed cardiac defects on testing but no overt clinical signs, 3 whereas a spontane ous and transmissible neurodegenerative disease developed in a second model. 4 After one of these models was infected with prions, extraneural de position of abnormal prion protein and of infec tious prions was seen in peripheral tissues. 9, 22 These observations in transgenic mice have paral lels with the patients we describe, and it is pos sible that poor ascertainment of diarrhea and autonomic dysfunction in mice explains the ap parent discrepancy in clinical presentation. A fur ther distinction is that the transgenic models have minimal brain parenchymal deposits of prion protein, whereas parenchymal prion pro tein amyloid plaques are prominent in patients with the Y163X mutation (Fig. 4A, 4B, and 4D) .
Autonomic failure and peripheral neuropathy are not major clinical features in the recognized inherited prion diseases. Dysautonomia has been reported in the rapidly progressive fatal familial insomnia, 23 which is classically caused by a mu tation at codon 178 24 in association with methio nine at polymorphic residue 129. However, pe ripheral neuropathy is not a feature of fatal familial insomnia. 25, 26 Inherited prion disease associated with the Y163X mutation is consis tently associated with autonomic failure, charac terized by severe parasympathetic and sympa thetic dysfunction. It is likely that the cause of autonomic failure is predominantly peripheral, as suggested by the clinical and electrophysio logical evidence and by evidence of pathologic features in the peripheral nervous system. Diar rhea in these patients has multiple potential causes and may be caused by autonomic dener vation of the bowel; alternatively, abnormal prion protein may have direct toxic effects on the mucosa causing malabsorption, bacterial over growth, or gastroparesis, as described in famil ial amyloid polyneuropathy. 27 Presentation with diarrhea led to invasive in vestigations or surgery in several patients, with concomitant potential for iatrogenic transmis sion of prions from the gut through contamina tion of medical or surgical instruments. 28 It is reassuring, however, that murine studies did not show experimental transmissibility, although this finding does not completely rule out the pres ence of potentially infectious human prions. Al though nonmutant prion protein was detected in the protein deposits in multiple tissues, Western blotting showed that the protein was not protease resistant. PRNP analysis should be considered in the investigation of unexplained chronic diarrhea associated with a neuropathy or an unexplained syndrome similar to familial amyloid polyneu ropathy. The prevalence of systemic amyloidosis associated with prion protein is probably low but might be better characterized with more wide spread testing of PRNP and histologic examina tion for prion protein in biopsy samples.
